Y Intercept Hong Kong Ltd Has $1.29 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Y Intercept Hong Kong Ltd lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 74.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,584 shares of the medical device company’s stock after selling 47,164 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in DexCom were worth $1,290,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Forvis Mazars Wealth Advisors LLC raised its stake in DexCom by 0.7% in the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock worth $1,359,000 after purchasing an additional 118 shares in the last quarter. Principal Securities Inc. raised its position in shares of DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after buying an additional 135 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after buying an additional 182 shares during the period. GPS Wealth Strategies Group LLC boosted its stake in shares of DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after buying an additional 185 shares during the period. Finally, Peterson Wealth Services grew its position in DexCom by 7.1% during the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock worth $236,000 after buying an additional 201 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DXCM opened at $89.91 on Thursday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a market cap of $35.13 billion, a PE ratio of 62.87, a PEG ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The business has a 50-day simple moving average of $84.29 and a two-hundred day simple moving average of $76.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Canaccord Genuity Group lifted their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.